Rapid, High-Throughput IgG Quantification Assay For Cell Line Development

By Silvia Vidali, PhD and Cathy Olsen, PhD, Molecular Devices

This content is brought to you by Molecular Devices, a Danaher Operating Company.

Biopharmaceuticals and biologics are essential in the treatment of numerous diseases. Recently, monoclonal antibodies (mAbs) have emerged as a significant advancement in improving treatment outcomes for a diverse array of human conditions, such as cancer, autoimmune diseases, infections, transplantation rejection, and inflammatory disorders. Despite their potential, the accessibility of these therapies is often hindered by their high costs. Antibody therapies typically require patients to receive large doses, which makes it crucial to develop reliable methods for producing cell lines with high antibody expression levels.

Learn more about how this would not only enhance the efficiency of production but also potentially reduce costs and make these life-saving treatments more accessible to a broader population.